Oppenheimer maintains Entrada stock Outperform with $30 target

On Monday, Oppenheimer reaffirmed its positive stance on Entrada Therapeutics (NASDAQ:TRDA), maintaining an Outperform rating and a $30.00 price target. The stock, currently trading at $10.78, sits near its 52-week low of $10.15, significantly below its high of $21.79. According to InvestingPro data, analysts maintain a strong bullish consensus on TRDA, with multiple analysts recently revising their earnings estimates upward. The endorsement follows Entrada Therapeutics’ recent announcement regarding the Medicines and Healthcare products Regulatory Agency’s (MHRA) authorization to commence the ELEVATE-45-201 study in the United Kingdom (TADAWUL:4280). This Phase 1/2 study is part of a global, two-part, multiple ascending dose (MAD) trial of ENTR-601-45, aimed at treating ambulatory Duchenne muscular dystrophy (DMD) patients who could benefit from exon-45 skipping. The initiation of this trial is anticipated in the third quarter of 2025.

The company’s recent progress includes the lifting of a clinical hold by the U.S. Food and Drug Administration (FDA) and subsequent authorizations by both the FDA and MHRA to start ELEVATE-44-102, a Phase 1/2 study of ENTR-601-44 for DMD patients amenable to exon-44 skipping, as well as ELEVATE-44-201 in the United States and United Kingdom. With a market capitalization of $374 million and a strong financial health score rated as "GREAT" by InvestingPro, the company appears well-positioned to execute its clinical development strategy.

Oppenheimer’s analysis suggests that these regulatory milestones have positioned Entrada Therapeutics advantageously to meet its objective of progressing three DMD-focused products into clinical development by the end of 2025. The firm’s reiterated Outperform rating and price target reflect confidence in the company’s trajectory and potential to reach its clinical development goals.

Entrada Therapeutics has been actively working to address the needs of patients with DMD, a genetic disorder characterized by progressive muscle degeneration. The company’s approach involves targeted therapies that aim to skip specific exons in the dystrophin gene, which is responsible for the symptoms of DMD. By advancing multiple products that cater to different exon skipping needs, Entrada Therapeutics is diversifying its potential treatment offerings for DMD.

The analyst’s statement underscores the significance of the recent regulatory authorizations, which are seen as critical steps forward for Entrada Therapeutics. With the MHRA’s green light for ELEVATE-45-201 and the earlier approvals for ELEVATE-44-102 and ELEVATE-44-201, the company is steadily moving toward its year-end 2025 goal. The company’s solid financial foundation, evidenced by a remarkable current ratio of 11.15 and more cash than debt on its balance sheet, supports its clinical development ambitions. Oppenheimer’s reiterated Outperform rating and $30 price target indicate a belief in the company’s continued progress and success in its clinical endeavors. For deeper insights into TRDA’s financial health and growth potential, InvestingPro subscribers have access to over 10 additional exclusive ProTips and comprehensive financial metrics.

In other recent news, Entrada Therapeutics reported a fourth-quarter earnings result of $37.4 million, primarily from collaboration revenue, with earnings per share of $0.03, surpassing both Oppenheimer’s projections and consensus estimates. Following this, Oppenheimer reiterated its Outperform rating and set a $30 price target for the company, reflecting confidence in Entrada’s ongoing development programs. Additionally, Entrada received authorization from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b clinical trial for ENTR-601-44, a potential treatment for Duchenne muscular dystrophy (DMD), marking a significant regulatory milestone. The FDA’s decision follows a similar approval from the UK’s Medicines and Healthcare Products Regulatory Agency for related studies. H.C. Wainwright maintained a Buy rating with a $20 price target, noting the FDA’s lift of a clinical hold as a critical step in reducing development risks. Entrada also received clearance from the UK to begin a Phase 1/2 trial for ENTR-601-45, targeting a specific mutation in the DMD gene. Roth/MKM maintained a Buy rating with a $23 price target, highlighting strong preclinical data and positive Phase 1 human volunteer study outcomes. These developments indicate continued progress in Entrada’s efforts to advance its DMD treatment programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.